Profile data is unavailable for this security.
About the company
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
- Revenue in USD (TTM)0.00
- Net income in USD-124.65m
- Incorporated2019
- Employees6.00
- LocationLENZ Therapeutics Inc445 Marine View Ave Suite 320DEL MAR 92014United StatesUSA
- Phone+1 (858) 925-7000
- Fax+1 (302) 658-3989
- Websitehttps://graphitebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADC Therapeutics SA | 69.56m | -240.05m | 405.79m | 273.00 | -- | -- | -- | 5.83 | -2.94 | -2.94 | 0.8528 | -1.80 | 0.1645 | 0.179 | 1.42 | 254,791.20 | -55.47 | -48.41 | -67.39 | -55.63 | 96.36 | -- | -337.16 | -308.62 | 4.73 | -4.70 | 1.55 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Tourmaline Bio Inc | 0.00 | -42.12m | 406.24m | 44.00 | -- | 1.57 | -- | -- | -10.18 | -10.18 | 0.00 | 10.08 | 0.00 | -- | -- | 0.00 | -20.85 | -- | -21.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -44.60m | 407.37m | 19.00 | -- | -- | -- | -- | -10.38 | -10.38 | 0.00 | -1.56 | 0.00 | -- | -- | 0.00 | -94.31 | -86.84 | -178.23 | -130.46 | -- | -- | -- | -769.76 | -- | -15.46 | 1.74 | -- | -- | -- | -5.33 | -- | -- | -- |
| Anika Therapeutics Inc | 166.66m | -82.67m | 409.12m | 357.00 | -- | 1.91 | -- | 2.45 | -5.64 | -5.64 | 11.37 | 14.48 | 0.5378 | 1.48 | 4.72 | 466,840.30 | -26.68 | -5.41 | -29.48 | -5.87 | 61.85 | 60.70 | -49.60 | -12.60 | 3.76 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| Revance Therapeutics Inc | 234.04m | -323.99m | 411.65m | 534.00 | -- | -- | -- | 1.76 | -3.81 | -3.81 | 2.77 | -1.72 | 0.4414 | 2.33 | 12.00 | -- | -61.11 | -55.55 | -72.36 | -63.20 | 68.23 | -- | -138.43 | -304.96 | 3.29 | -36.36 | 1.54 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| iTeos Therapeutics Inc | 12.60m | -112.64m | 419.36m | 157.00 | -- | 0.7265 | -- | 33.30 | -3.15 | -3.15 | 0.3522 | 16.05 | 0.0177 | -- | 2.82 | 80,222.93 | -15.84 | 5.84 | -16.81 | 7.02 | -- | -- | -894.35 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| OraSure Technologies, Inc. | 405.47m | 53.66m | 420.04m | 638.00 | 7.62 | 0.9373 | 5.63 | 1.04 | 0.7204 | 0.7204 | 5.47 | 5.86 | 0.8748 | 3.15 | 7.31 | 635,536.10 | 11.58 | 0.7238 | 13.11 | 0.8212 | 44.25 | 46.94 | 13.23 | 1.13 | 8.57 | -- | 0.0018 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
| Lenz Therapeutics Inc | 0.00 | -124.65m | 420.30m | 6.00 | -- | 0.743 | -- | -- | -15.35 | -15.35 | 0.00 | 22.15 | 0.00 | -- | -- | 0.00 | -48.85 | -- | -50.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -66.39m | 420.71m | 58.00 | -- | 3.00 | -- | -- | -2.69 | -2.69 | 0.00 | 4.26 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0153 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Cibus Inc | 1.82m | -267.63m | 422.50m | 183.00 | -- | 1.20 | -- | 232.52 | -22.63 | -22.63 | 0.1769 | 14.27 | 0.0064 | -- | -- | 9,928.96 | -119.13 | -86.28 | -135.32 | -96.45 | 2.31 | -- | -18,582.22 | -792.07 | -- | -3.70 | 0.0049 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
| Mersana Therapeutics Inc | 36.86m | -171.67m | 423.37m | 123.00 | -- | 11.32 | -- | 11.49 | -1.50 | -1.50 | 0.3175 | 0.3057 | 0.1315 | -- | 2.46 | 299,634.20 | -61.27 | -61.68 | -84.73 | -81.35 | -- | -- | -465.80 | -622.19 | -- | -- | 0.408 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Replimune Group Inc | 0.00 | -209.96m | 426.65m | 284.00 | -- | 1.01 | -- | -- | -3.16 | -3.16 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -34.66 | -26.12 | -36.63 | -27.31 | -- | -- | -- | -- | -- | -- | 0.1436 | -- | -- | -- | -47.65 | -- | 75.59 | -- |
| Lexicon Pharmaceuticals Inc | 2.31m | -193.58m | 428.45m | 285.00 | -- | 1.48 | -- | 185.40 | -0.8257 | -0.8257 | 0.0098 | 1.17 | 0.008 | -- | 2.59 | 8,108.77 | -66.76 | -24.41 | -72.21 | -29.01 | 94.98 | 98.49 | -8,376.55 | -84.92 | 15.56 | -11.46 | 0.2569 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| ACELYRIN Inc | 0.00 | -381.64m | 430.27m | 130.00 | -- | 0.6486 | -- | -- | -10.84 | -10.84 | 0.00 | 6.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Tscan Therapeutics Inc | 21.05m | -89.22m | 430.59m | 154.00 | -- | 2.71 | -- | 20.46 | -2.49 | -2.49 | 0.4421 | 3.15 | 0.0893 | -- | -- | 136,681.80 | -37.87 | -- | -42.07 | -- | -- | -- | -423.86 | -- | -- | -- | 0.1661 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Entrada Therapeutics Inc | 129.01m | -6.69m | 442.19m | 159.00 | -- | 1.82 | -- | 3.43 | -0.2543 | -0.2543 | 3.86 | 7.25 | 0.3578 | -- | -- | 811,402.50 | -1.85 | -- | -2.47 | -- | -- | -- | -5.18 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to LENZ Therapeutics Inc's reporting currency: US Dollar USD
62.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Alpha Wave Global LPas of 21 Mar 2024 | 3.61m | 43.42% |
| Point72 Asset Management LPas of 21 Mar 2024 | 1.88m | 7.37% |
| EcoR1 Capital, LLCas of 21 Mar 2024 | 1.22m | 4.78% |
| RA Capital Management LPas of 21 Mar 2024 | 607.27k | 2.38% |
| Tang Capital Management LLCas of 24 Jan 2024 | 445.41k | 1.74% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 227.56k | 0.89% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 199.17k | 0.78% |
| Prosight Management LPas of 31 Dec 2023 | 193.13k | 0.76% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 117.28k | 0.46% |
| Stanford Management Co.as of 31 Dec 2023 | 100.44k | 0.39% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
